HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Excimer Lasers

Subscribe to New Research on Excimer Lasers

Gas lasers with excited dimers (i.e., excimers) as the active medium. The most commonly used are rare gas monohalides (e.g., argon fluoride, xenon chloride). Their principal emission wavelengths are in the ultraviolet range and depend on the monohalide used (e.g., 193 nm for ArF, 308 nm for Xe Cl). These lasers are operated in pulsed and Q-switched modes and used in photoablative decomposition involving actual removal of tissue. (UMDNS, 2005)

Also Known As:

Lasers, Excimer; ArF Excimer Lasers; ArF Lasers; Argon Fluoride Lasers; Excimer Laser; Excimer Lasers, ArF; Excimer Lasers, Argon Fluoride; Excimer Lasers, KrCl; Excimer Lasers, Krypton Chloride; Excimer Lasers, XeCl; Excimer Lasers, Xenon Chloride; KrCl Excimer Lasers; Krypton Chloride Lasers; Lasers, ArF Excimer; Lasers, Argon Fluoride Excimer; Lasers, KrCl; Lasers, Krypton Chloride; Lasers, Krypton Chloride Excimer; Lasers, XeCl Excimer; Lasers, Xenon Chloride; Lasers, Xenon Chloride Excimer; XeCl Lasers; Xenon Chloride Lasers; ArF Excimer Laser; ArF Laser; Argon Fluoride Laser; Chloride Laser, Krypton; Chloride Laser, Xenon; Chloride Lasers, Krypton; Chloride Lasers, Xenon; Excimer Laser, ArF; Excimer Laser, KrCl; Excimer Laser, XeCl; Fluoride Laser, Argon; Fluoride Lasers, Argon; KrCl Excimer Laser; KrCl Laser; KrCl Lasers; Krypton Chloride Laser; Laser, ArF; Laser, ArF Excimer; Laser, Argon Fluoride; Laser, Excimer; Laser, KrCl; Laser, KrCl Excimer; Laser, Krypton Chloride; Laser, XeCl; Laser, XeCl Excimer; Laser, Xenon Chloride; Lasers, ArF; Lasers, Argon Fluoride; Lasers, KrCl Excimer; Lasers, XeCl; XeCl Excimer Laser; XeCl Excimer Lasers; XeCl Laser; Xenon Chloride Laser; Argon Fluoride Excimer Lasers; Krypton Chloride Excimer Lasers; Xenon Chloride Excimer Lasers

Networked: 1264 relevant articles (143 outcomes, 135 trials/studies) for this Therapy, Comments

Relationship Network

Therapy Context: Research Results

Equipment and Supplies
- Optical Devices: 122
  - Lasers: 20842
    - Excimer Lasers: 1264
- Radiation Equipment and Supplies
  - Lasers: 20842
    - Excimer Lasers: 1264

Experts

1.	Manche, Edward E: 11 articles (08/2008 - 01/2002)
2.	Seitz, Berthold: 11 articles (11/2007 - 01/2002)
3.	Langenbucher, Achim: 11 articles (11/2007 - 01/2002)
4.	Topaz, On: 10 articles (11/2009 - 04/2002)
5.	Alió, Jorge L: 10 articles (07/2009 - 07/2004)
6.	Tulleken, Cornelis A F: 8 articles (03/2010 - 10/2002)
7.	van der Zwan, Albert: 7 articles (03/2010 - 10/2002)
8.	Dahm, Johannes B: 7 articles (01/2008 - 07/2002)
9.	Naumann, Gottfried O H: 7 articles (11/2007 - 05/2002)
10.	Taylor, Charles R: 7 articles (05/2004 - 05/2002)

Related Diseases

1.	Myopia 08/01/2006 - "CONCLUSIONS: Bilateral refractive lensectomy is effective for improving functional vision in neurobehaviorally impaired children who have high myopia (beyond the range of excimer laser correction: see companion publication) and difficulties wearing glasses. " 01/01/1997 - "CONCLUSIONS: MLK is effective in high myopia treatment and has some special advantages compared with radial keratotomy, photorefractive keratectomy, automated lamellar keratoplasty and excimer laser in situ keratomileusis. " 04/01/1995 - "CONCLUSIONS: Excimer laser photorefractive keratectomy is an alternative means of treating high and extreme myopia and can cause a significant reduction in myopia. " 04/01/1995 - "We assessed the efficacy of excimer laser treatment for persons with high (spherical equivalent between -5 and -10 diopters) and extreme (spherical equivalent greater than -10D) myopia. " 11/01/2000 - "CONCLUSION: PRK and LASIK with the Nidek EC-5000 excimer laser are effective and safe for correcting low to moderate myopia, but LASIK eyes showed better results for moderate myopia in terms of uncorrected visual acuity." Order ALL the reference details at left...
2.	Astigmatism 07/01/2000 - "One eye (1.7%) lost 2 or more lines of best spectacle-corrected visual acuity.CONCLUSION: Photoastigmatic refractive keratectomy with the Summit Apex Plus excimer laser is a safe and effective method of reducing compound myopic astigmatism. " 05/01/1996 - "OBJECTIVE: To study the efficacy of excimer laser photorefractive keratectomy (PRK) for high, moderate, and low degrees of primary myopic astigmatism. " 11/01/2004 - "The number of reoperations and residual refractive defects were significantly better in Group 2. CONCLUSION: The 2-step technique improved the accuracy of excimer laser correction of post-PKP astigmatism." 09/01/2002 - "CONCLUSIONS: Photorefractive keratectomy with the MEL-70 excimer laser to correct myopic astigmatism was a safe and effective procedure with good stability at six months' follow-up. " 03/01/2000 - "CONCLUSIONS: The efficacy of LASIK after penetrating keratoplasty was good compared to incisional or surface based excimer laser methods and has the advantage of reducing the myopic spherical equivalent refraction in addition to astigmatism, thus improving the uncorrected visual acuities." Order ALL the reference details at left...
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/2004 - "The most recent form of phototherapy, 308-nm excimer laser, holds promise for becoming a useful tool in the treatment of stable, localized psoriasis." 11/01/2007 - "Excimer laser treatment for psoriasis has been associated with good results at a lower cumulative dose than narrowband ultraviolet (UV)B protocols. " 05/01/2002 - "CONCLUSION: As little as one high-dose excimer laser treatment can be effective for localized plaque-type psoriasis. " 12/01/2007 - "CONCLUSION: Our clinical data suggest that treatment of psoriasis vulgaris by a 308 nm excimer laser is effective and safe, and it is more efficacious in macular type than in chronic plaque type." 08/01/2007 - "CONCLUSION: The possible explanations for the superior efficacy of the excimer laser over traditional UVB therapy for psoriasis include: 1) a higher intensity UV light to plaques, which is more effective in clearing psoriasis; 2) penetration into the dermis where it may induce T cell apoptosis, potentially to a greater extent than the wavelength or given energy level predicts; and 3) the difference in the delivery of UVB light may result in cell death and skin immune system suppression more effectively than traditional UVB." Order ALL the reference details at left...
4.	Vitiligo 10/01/2007 - "CONCLUSIONS: The 308-nm excimer laser is effective for therapy to treat vitiligo on the face and neck. " 05/01/2005 - "CONCLUSIONS: 308-nm excimer laser therapy is effective against vitiligo. " 03/01/2004 - "Narrow-band UVB therapy has been shown to be effective and safe for use in the management of vitiligo; its wavelength is not so different from 308 nm XeCl excimer laser radiation. " 03/01/2009 - "Treatment with a 308-nm excimer laser has shown promising results in patients with vitiligo. " 02/01/2009 - "CONCLUSION: The 308 nm excimer laser is safe and effective in treating stable vitiligo and the efficacy varies in different lesion sites." Order ALL the reference details at left...
5.	Hyperopia (Hypermetropia) 11/01/1999 - "OBJECTIVE: To evaluate safety and efficacy of excimer laser in situ keratomileusis (LASIK) for high and moderate hyperopia. " 11/01/1999 - "CONCLUSION: LASIK with the Keracor 117CT excimer laser appears to be an effective and safe procedure to correct hyperopia. " 01/01/1998 - "CONCLUSION: Excimer laser keratomileusis in situ with the Keracor 116 appears to be an effective and safe procedure to decrease low and moderate hyperopia, but the predictability of the procedure needs improvement." 07/01/2009 - "CONCLUSION: Excimer laser LASIK was safe and effective for treating hyperopia up to +6.25 D with no further loss of CDVA lines after enhancement." 09/01/1998 - "BACKGROUND: This paper presents the results over a 2-year follow-up of the first human trial of photorefractive keratectomy (PRK) for correction of hyperopia using an erodible disc excimer laser delivery system (Summit) coupled to an axicon lens. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	xenon chloride
2.	chiron
3.	Hyaluronic Acid (Hyaluronan)
4.	Indomethacin (Indometacin)
5.	glucuronyl glucosamine glycan sulfate (Vessel)
6.	AT-308 (AT 308)
7.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
8.	Tacrolimus (Prograf)
9.	Fluconazole (Zonal)
10.	Ketorolac

Related Therapies and Procedures

1.	Laser In Situ Keratomileusis (LASIK)
2.	Photorefractive Keratectomy
3.	Angioplasty (Angioplasties)
4.	Lasers (Laser)
5.	Penetrating Keratoplasty

blog comments powered by Disqus

TREATMENT OPTIONS
for Myopia,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 252 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>